124 related articles for article (PubMed ID: 12404910)
1. [Characterisation of families with hereditary prostate cancer in the Netherlands].
Meulenbeld HJ; Verhage BA; Kil PJ; Kiemeney LA; Vasen HF
Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1938-42. PubMed ID: 12404910
[TBL] [Abstract][Full Text] [Related]
2. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
3. Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer.
Johanneson B; Deutsch K; McIntosh L; Friedrichsen-Karyadi DM; Janer M; Kwon EM; Iwasaki L; Hood L; Ostrander EA; Stanford JL
Prostate; 2007 May; 67(7):732-42. PubMed ID: 17372923
[TBL] [Abstract][Full Text] [Related]
4. Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations.
Grönberg H; Wiklund F; Damber JE
Cancer; 1999 Aug; 86(3):477-83. PubMed ID: 10430256
[TBL] [Abstract][Full Text] [Related]
5. [Epidemiology of familial prostatic cancer: 4-year assessment of French studies].
Valeri A; Drelon E; Azzouzi R; Delannoy A; Teillac P; Fournier G; Mangin P; Berthon P; Cussenot O
Prog Urol; 1999 Sep; 9(4):672-9. PubMed ID: 10555220
[TBL] [Abstract][Full Text] [Related]
6. Role of HPC2/ELAC2 in hereditary prostate cancer.
Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Res; 2001 Sep; 61(17):6494-9. PubMed ID: 11522646
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer in Dutch hereditary prostate cancer families.
Kiemeney LA; Broeders MJ; Pelger M; Kil PJ; Schröder FH; Witjes JA; Vasen HF
Int J Cancer; 2008 Feb; 122(4):871-6. PubMed ID: 17957791
[TBL] [Abstract][Full Text] [Related]
8. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
9. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
[TBL] [Abstract][Full Text] [Related]
10. The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.
Cremers RG; Aben KK; van Oort IM; Sedelaar JP; Vasen HF; Vermeulen SH; Kiemeney LA
Prostate; 2016 Jul; 76(10):897-904. PubMed ID: 26989049
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
12. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
[TBL] [Abstract][Full Text] [Related]
13. Higher frequency of familial clustering of prostate cancer in French-Canadian men.
Filion E; Taussky D; Bahary JP; Maugard CM
J Urol; 2007 Oct; 178(4 Pt 1):1265-9; discussion 1270. PubMed ID: 17698103
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
15. Population-based risk assessment for other cancers in relatives of hereditary prostate cancer (HPC) cases.
Albright LA; Schwab A; Camp NJ; Farnham JS; Thomas A
Prostate; 2005 Sep; 64(4):347-55. PubMed ID: 15754348
[TBL] [Abstract][Full Text] [Related]
16. Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer.
Kuller LH; Thomas A; Grandits G; Neaton JD;
Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):373-7. PubMed ID: 15006911
[TBL] [Abstract][Full Text] [Related]
17. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
Coard KC; Skeete DH
BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
[TBL] [Abstract][Full Text] [Related]
18. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J; Lange EM; Isaacs SD; Liu W; Wiley KE; Lange L; Gronberg H; Duggan D; Carpten JD; Walsh PC; Xu J; Chang BL; Isaacs WB; Zheng SL
Prostate; 2008 Apr; 68(5):489-97. PubMed ID: 18213635
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
20. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
